Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-C...

por Ramalingam, Suresh S., Blackhall, Fiona, Krzakowski, Maciej, Barrios, Carlos H., Park, Keunchil, Bover, Isabel, Seog Heo, Dae, Rosell, Rafael, Talbot, Denis C., Frank, Richard, Letrent, Stephen P., Ruiz-Garcia, Ana, Taylor, Ian, Liang, Jane Q., Campbell, Alicyn K., O'Connell, Joseph, Boyer, Michael
Publicado no J Clin Oncol (2012)